New weekly injections can change the lives of over 8 million people who live together Parkinson’s diseasepotentially replaces the need for daily tablets.
Scientists at the University of South Australia (UNISA) have developed a long-acting, injectable formulation that provides two important Parkinson’s disease over a week.
According to the Parkinsons Foundation, there is currently no treatment for Parkinson’s disease, the second most common neurological disorder and the second most common neurological disorder.
Patients usually take daily to manage symptoms such as tremor, stiffness, and slow movement Oral medicationAccording to a university press release, such as Levodopa and Calbidopa.
This method can be particularly difficult for individuals who have difficulty swallowing or are unable to take pills consistently, with irregular dosage levels, increased side effects, and reduced efficacy
Levodopa is the “standard gold therapy for Parkinson’s disease,” according to UNISA’s lead investigator Professor Sanjay Garg, but its short life expectancy means it needs to be taken several times a day.
The researchers tested injectable gel implants that combine FDA-approved biodegradables with pH-sensitive substances to achieve controlled, sustained drug release.
Parkinson’s patients taking “magic mushrooms” see important benefits, according to research
The gel is injected through a single shot under the skin or into the muscle tissue. This states that there is no need for surgical implants and the discomfort is minimal.
The team found that Gel gradually released major Parkinsonian medications (90% of levodopa drugs and 81% of carbohydrates) over the course of a week.
The findings were published in Journal Drug Delivery and Translational Research.
“Reducing the frequency of administration from multiple times a day to weekly injections is a major step forward in Parkinson’s treatment,” Garg said in the release. “We are not only improving the way we deliver medicines. We are Improve the lives of patients. ”
Extensive lab testing has confirmed the effectiveness and safety of the system.
The implants deteriorated by more than 80% within one week and showed no significant toxicity in cell viability tests.
“The meaning of this study is deep,” Garg added.
Deepa Nakmode, a doctoral student at the University of South Australia, noted that the method is designed to steadily release both levodopa and carbonated pa over a week, maintaining consistent plasma levels and reducing the risks associated with fluctuating drug concentrations.
“Years later Intensive researchIt’s extremely rewarding to see Parkinson’s disease in long-acting injection innovations reach this stage,” he said in the release.
The team’s invention is currently being filed for an Australian patent, Nakmode added.
This technology can also be adapted to other chronic diseases. Cancer etc.According to Garg, diabetes, neurodegenerative disorders, chronic pain, and infectious diseases requiring long-term drug delivery.
Click here to sign up for our health newsletter
The system can be adjusted to release the drug over a period of several days to weeks, depending on your treatment needs.
Visit us for more health articles www.foxnews.com/health
Scientists hope to begin clinical trials in the near future and explore opportunities for gel to be sold on the market.
